Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | checkpoint kinase 1 | Starlite/ChEMBL | References |
Homo sapiens | WEE1 G2 checkpoint kinase | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 7.89 | Inhibition of human Wee1 | ChEMBL. | 18976834 |
IC50 (binding) | = 0.013 uM | Inhibition of human Wee1 in presence of 9.5 uM ATP | ChEMBL. | 16884302 |
IC50 (binding) | = 0.013 uM | Inhibition of human Wee1 in presence of 9.5 uM ATP | ChEMBL. | 16884302 |
IC50 (binding) | = 0.013 uM | Inhibition of human Wee1 | ChEMBL. | 18976834 |
IC50 (binding) | = 0.62 uM | Inhibition at human Chk1 in presence of 4 uM ATP | ChEMBL. | 16884302 |
IC50 (binding) | = 0.62 uM | Inhibition at human Chk1 in presence of 4 uM ATP | ChEMBL. | 16884302 |
Ratio IC50 (binding) | = 48 | Ratio of IC50 for Chk1/IC50 for Wee1 | ChEMBL. | 16884302 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.